Clascoterone Cream 1% in Acne Management: Case Series and Real-World Canadian Experience

March 2025 in “ Canadian dermatology today. ”

Wei Jing Loo

clascoterone acne vulgaris hirsutism hidradenitis suppurativa retinoid-induced dermatitis androgenetic alopecia folliculitis laser-induced acne flares

Studysummary In this case series, treatment with clascoterone cream 1% was reported to be effective and well tolerated for diverse acne vulgaris patients, improving clinical outcomes whether used alone or in combination with other therapies, and addressing various other skin conditions.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

This case series examined the use of clascoterone cream 1% in 10 patients with acne vulgaris from August 2023 to May 2024. The treatment was found to be effective and well-tolerated across various severities, ages, genders, and ethnicities. Clascoterone cream 1% showed clinical improvement as a monotherapy, in combination with other treatments, and as maintenance therapy to prevent acne relapse. Additionally, it addressed other conditions such as hirsutism, hidradenitis suppurativa, retinoid-induced dermatitis, androgenetic alopecia, folliculitis, and laser-induced acne flares. This real-world experience supports the cream's effectiveness, tolerability, and versatility for diverse patients with acne vulgaris.

View this study on canadiandermatologytoday.com →

Discuss this study in the Community →

Research cited in this study

4 / 4 results

research Guidelines of Care for the Management of Acne Vulgaris

5 citations , January 2024 in “Journal of the American Academy of Dermatology”

This study provided 18 evidence-based recommendations for managing acne vulgaris, strongly endorsing treatments like benzoyl peroxide, topical retinoids, and oral isotretinoin for severe cases, and issued conditional recommendations for therapies like salicylic acid and spironolactone, while offering good practice statements on combining treatment methods.

research Use of Topical Clascoterone for the Treatment of Hidradenitis Suppurativa

10 citations , April 2023 in “JAAD Case Reports”

This article discusses the challenges in treating hidradenitis suppurativa, highlighting that adalimumab is currently the only FDA-approved treatment, and reports no clinical results.

research Clascoterone as a Novel Treatment for Androgenetic Alopecia

5 citations , May 2020 in “Clinical and Experimental Dermatology”

This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.

A Summary of In Vitro, Phase I, and Phase II Studies Evaluating the Mechanism of Action, Safety, and Efficacy of Clascoterone (Cortexolone 17a Propionate, CB-03-01) in Androgenetic Alopecia

research A Summary of In Vitro, Phase I, and Phase II Studies Evaluating the Mechanism of Action, Safety, and Efficacy of Clascoterone (Cortexolone 17a Propionate, CB-03-01) in Androgenetic Alopecia

3 citations , August 2019 in “Journal of The American Academy of Dermatology”

Clascoterone safely promotes hair growth similar to minoxidil.